Evidence map›Paper›PMID 42487875›Full record

ArticleTransfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie2026

Chondrogenic Potential of Periosteum-Derived Cells.

Sarah Hochmann, Gabriele Brachtl, Rodolphe Poupardin, Anna Hoog, Michaela Mittermeir, Anna Maria Raninger, Katharina Schallmoser, Jörn Wittig, Martin Textor, Sven Geissler and 2 more

Abstract read
In one paragraph

Article in Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sarah HochmannInstitute for Experimental and Clinical Cell Therapy, Paracelsus Medical Private University Salzburg, Salzburg, Austria.
Gabriele BrachtlInstitute for Experimental and Clinical Cell Therapy, Paracelsus Medical Private University Salzburg, Salzburg, Austria.
Rodolphe PoupardinInstitute for Experimental and Clinical Cell Therapy, Paracelsus Medical Private University Salzburg, Salzburg, Austria.
Anna HoogInstitute for Experimental and Clinical Cell Therapy, Paracelsus Medical Private University Salzburg, Salzburg, Austria.
Michaela MittermeirInstitute for Experimental and Clinical Cell Therapy, Paracelsus Medical Private University Salzburg, Salzburg, Austria.
Anna Maria RaningerInstitute for Experimental and Clinical Cell Therapy, Paracelsus Medical Private University Salzburg, Salzburg, Austria.
Katharina SchallmoserInstitute for Transfusion Medicine, Paracelsus Medical Private University Salzburg, Salzburg, Austria.
Jörn WittigDepartment of Oral and Maxillofacial Surgery, Paracelsus Medical Private University Salzburg, Salzburg, Austria.
Martin TextorCenter for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.
Sven GeisslerCenter for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.
Alexander GagglDepartment of Oral and Maxillofacial Surgery, Paracelsus Medical Private University Salzburg, Salzburg, Austria.
Dirk StrunkInstitute for Experimental and Clinical Cell Therapy, Paracelsus Medical Private University Salzburg, Salzburg, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Successful bone regeneration after dental and craniofacial reconstruction can present a significant clinical challenge. In this study, we investigated whether the regenerative potential of human periosteum-derived stromal progenitor cells (PDCs) depends on their anatomical origin. Methods: Paired periosteum samples were collected from jaw and appendicular bones (fibula, femur, or iliac crest) of five donors and expanded in a xeno-free, platelet lysate-supplemented medium. All cultures exhibited a typical fibroblastic morphology and a uniform stromal immunophenotype (≥95% CD73/90/105 and ≤2% CD45/14/19/HLA-DR). PDCs were tested in a 3D cartilage disc formation assay after seeding on collagen-coated transwell inserts or on transferrable porcine collagen membranes. Results: Appendicular-derived PDCs consistently formed stable, cartilage-like 3D discs with a mean weight of 14.7 mg and a range of 8.8-23.6 mg, whereas jaw-derived PDCs produced contracted, irregular aggregates. Histological and molecular analyses confirmed greater proteoglycan deposition and higher Conclusion: Our findings demonstrate that the chondrogenic potential of PDCs is strongly determined by their anatomical origin. Therefore, selecting the appropriate periosteal source, combined with optimized biomaterials, is crucial for achieving predictable and efficient bone regeneration.

Indexed as

ChondrogenesisPeriosteumPlatelet lysateRegenerative medicineStromal cells

Identifiers

PMID42487875
PMCPMC13391089

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.